The stock of Alder Biopharmaceuticals Incorporated (NASDAQ:ALDR) registered a decrease of 4.03% in short interest. ALDR’s total short interest was 7.79M shares in September as published by FINRA. Its down 4.03% from 8.12M shares, reported previously. With 654,000 shares average volume, it will take short sellers 12 days to cover their ALDR’s short positions. The short interest to Alder Biopharmaceuticals Incorporated’s float is 21.87%. About 417,080 shares traded hands. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has risen 55.86% since February 8, 2016 and is uptrending. It has outperformed by 39.37% the S&P500.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.65 billion. The Firm discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. It currently has negative earnings. The Firm has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Out of 4 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alder Biopharmaceuticals has been the topic of 5 analyst reports since October 15, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock on July 27 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.